NCT01090661View on ClinicalTrials.gov

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Healthy
Interventions
DRUG

mipomersen sodium

200 mg of mipomersen intravenous (IV) (single dose)

DRUG

mipomersen sodium

200 mg of mipomersen subcutaneous (SC) (single dose)

DRUG

moxifloxacin hydrochloride (Avelox®)

400 mg of moxifloxacin intravenous (IV) single dose

DRUG

placebo

placebo intravenous (IV) single dose

DRUG

placebo

placebo subcutaneous (SC) single dose

Trial Locations (1)

Unknown

PPD Development, LP, Austin

Sponsors
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Kastle Therapeutics, LLC

INDUSTRY